Arrayit Corporation (OTCBB: ARYC), a proprietary life sciences technology leader, is making available a Biomarker Discovery Service capable of identifying multiple new major genetic links for human disease states which have remained a mystery for years. In separate technology collaborations, Arrayit has conducted confidential experiments which have successfully proven the unique capabilities of the custom Arrayit products and protocols employed in the Biomarker Discovery Service. Publications are expected from the respective technology collaborators.
Paul K. Haje, VP of Sales and Marketing, stated, "By identifying the genes, scientists can develop therapies and drugs that take advantage of Arrayit's unique insight to substantially correct or cure the disease states."
Arrayit offers a Biomarker Discovery Program wherein DNA or RNA samples are analyzed on a custom microarray -- a small glass substrate containing a proprietary representation of the entire human genome -- for a contract fee that ranges between 100K and one million dollars per experiment. Arrayit retains a small percentage of each discovery as a downstream royalty, with the specific discoveries remaining the confidential property of the client.
New genetic variants could raise a woman's risk of cervical cancer from HPV infections